ClinicalTrials.gg
CompletedNCT05136885Updated May 14, 2025Results posted

HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose

A Phase 2/3 interventional study of SLS-005 and Matching Placebo in Amyotrophic Lateral Sclerosis, sponsored by Merit E. Cudkowicz, MD. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-14.

Sponsored by Merit E. Cudkowicz, MD · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Enrollment
49th of 307
161 · median 33
Started
2022
with 18 others
Phase 2/3
18 of 440
1 open now
Registered
309th of 440
by date
Lead sponsor
9 of 440
Merit E. Cudkowicz, MD

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 49th largest by enrollment of the 307 interventional ones that give a count, is one of 19 that started in 2022, is one of 18 in phase 2/3, and was the 309th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

Regimen E will evaluate the safety and efficacy of a single study drug, SLS-005 (Trehalose injection, 90.5 mg/mL for intravenous infusion) in participants with ALS.

Read the detailed description

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. This trial is designed as a perpetual platform trial. This means that there is a single Master Protocol dictating the conduct of the trial. The HEALEY ALS Platform Trial Master Protocol is registered as NCT04297683.

Once a participant enrolls into the Master Protocol and meets all eligibility criteria, the participant will be eligible to be randomized into any currently enrolling regimen. All participants will have an equal chance of being randomized to any currently enrolling regimen.

If a participant is randomized to Regimen E SLS-005 - Trehalose, the participant will complete a screening visit to assess additional Regimen E eligibility criteria. Once Regimen E eligibility criteria are confirmed, participants will complete a baseline assessment and be randomized in a 3:1 ratio to either active SLS-005 or matching placebo.

Regimen E will enroll by invitation, as participants may not choose to enroll in Regimen E. Participants must first enroll into the Master Protocol and be eligible to participate in the Master Protocol before being able to be randomly assigned to Regimen E.

For a list of enrolling sites, please see the HEALEY ALS Platform Trial Master Protocol under NCT04297683.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • ALS
  • Placebo-Controlled
  • Double-Blind
  • Regimen Specific Appendix
  • Lou Gehrig's Disease
  • Trehalose
  • Seelos Therapeutics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).

Exclusion criteria

Exclusion Criteria:

  • The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).

    1. Current diagnosis or healthcare professional-recommended treatment (medication, exercise or diet) of diabetes mellitus
    2. Master Protocol screening glucose >140 mg/dl
    3. Prior treatment with IV trehalose or known to trehalose
    4. Current use of oral trehalose (see prohibited medication Section 5.9)
    5. Inability for participant to return to site for weekly drug administration, until approved for home infusions
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    SLS-005

    SLS-005 is administered via infusion once weekly for 24 weeks.

    Drug: SLS-005

  • Placebo comparator
    Matching Placebo

    Matching placebo is administered via infusion once weekly for 24 weeks.

    Drug: Matching Placebo

Interventions

  • Administration: Infusion Dose: 0.75 g/kg weekly

  • DrugMatching Placebo

    Administration: Infusion Dose: equivalent weight-based volume as described for trehalose

06

What researchers measure

Primary outcomes

  1. Disease Progression as Assessed by the ALSFRS-R Slope

    Change in disease severity over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.

    Time frame: 24 Weeks

  2. Mortality Event Rate

    Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The rate of mortality was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times.

    Time frame: Baseline to 24 Weeks

Secondary outcomes

  1. Respiratory Function

    Change in respiratory function over time as measured by Slow Vital Capacity (SVC).

    Time frame: Baseline to 24 Weeks

  2. Muscle Strength

    Change in muscle strength over time as measured isometrically using hand-held dynamometry (HHD).

    Time frame: Baseline to 24 Weeks

  3. Number of Participants That Experienced Death or Death Equivalent

    The number of participants who died or met the criterion for a death equivalent from the date of their baseline visit to the end of the Week 24 visit window (generally 175 days after baseline). The death equivalent criterion is the use of permanent assisted ventilation (PAV) for more than 22 hours per day for more than 7 days in a row.

    Time frame: Baseline to 24 Weeks

07

Results

Posted Aug 28, 2024

Participant flow

Participant flow — Overall Study
MilestoneSLS-005Matching Placebo
Started12041
Completed9237
Not completed284

Outcome measures

PrimaryDisease Progression as Assessed by the ALSFRS-R Slope

Change in disease severity over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.

Time frame:
24 Weeks
Reported as:
Mean · points per month
Disease Progression as Assessed by the ALSFRS-R Slope
points per monthSLS-005Matching Placebo
Disease Progression as Assessed by the ALSFRS-R Slope-0.91 ± 0.090-1.06 ± 0.091
Statistical analysis
  • SLS-005 vs Matching Placebo · Bayesian shared-parameter model · Disease rate ratio: 0.87 · 95% CI 0.665 to 1.102DDR \<1 imply slowing of disease progression by Trehalose relative to placebo.Note: reported "Confidence Interval" is actually a Bayesian credible interval.
PrimaryMortality Event Rate

Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The rate of mortality was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times.

Time frame:
Baseline to 24 Weeks
Reported as:
Mean · events per month
Mortality Event Rate
events per monthSLS-005Matching Placebo
Mortality Event Rate0.010 ± 0.00250.012 ± 0.0027
SecondaryRespiratory Function

Change in respiratory function over time as measured by Slow Vital Capacity (SVC).

Time frame:
Baseline to 24 Weeks
Reported as:
Least squares mean · percent change
Respiratory Function
percent changeSLS-005Matching Placebo
Respiratory Function-11.40 ± 1.431-10.85 ± 1.089
Statistical analysis
  • SLS-005 vs Matching Placebo · Mixed Models Analysis · p = 0.7607 · Mean difference (net): -0.55 · 95% CI -4.06 to 2.97Trehalose 24-week change from baseline relative to placebo 24-week change from baseline.
SecondaryMuscle Strength

Change in muscle strength over time as measured isometrically using hand-held dynamometry (HHD).

Time frame:
Baseline to 24 Weeks
Reported as:
Least squares mean · percent change
Muscle Strength
percent changeSLS-005Matching Placebo
Muscle Strength-26.19 ± 2.568-27.11 ± 1.876
Statistical analysis
  • SLS-005 vs Matching Placebo · Mixed Models Analysis · p = 0.7737 · Mean difference (net): 0.92 · 95% CI -5.37 to 7.21Trehalose 24-week change from baseline relative to placebo 24-week change from baseline.
SecondaryNumber of Participants That Experienced Death or Death Equivalent

The number of participants who died or met the criterion for a death equivalent from the date of their baseline visit to the end of the Week 24 visit window (generally 175 days after baseline). The death equivalent criterion is the use of permanent assisted ventilation (PAV) for more than 22 hours per day for more than 7 days in a row.

Time frame:
Baseline to 24 Weeks
Reported as:
Count of participants · Participants
Number of Participants That Experienced Death or Death Equivalent
ParticipantsSLS-005Matching Placebo
Number of Participants That Experienced Death or Death Equivalent1010
Statistical analysis
  • SLS-005 vs Matching Placebo · Log Rank · p = 0.2137

Adverse events

Collected over Up to 35 weeks after participant signed Master Protocol consent.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SLS-0056/120 (5%)19/120 (15.8%)107/120 (89.2%)
Matching Placebo0/41 (0%)3/41 (7.3%)33/41 (80.5%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventSLS-005Matching Placebo
Acute respiratory failureRespiratory, thoracic and mediastinal disorders3/1200/41
Amyotrophic lateral sclerosisNervous system disorders3/1200/41
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders1/1201/41
Hip fractureInjury, poisoning and procedural complications1/1201/41
Subdural haemorrhageInjury, poisoning and procedural complications0/1201/41
Colitis ischaemicGastrointestinal disorders0/1201/41
Respiratory failureRespiratory, thoracic and mediastinal disorders2/1200/41
COVID-19Infections and infestations2/1200/41
PneumoniaInfections and infestations2/1200/41
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/1200/41
Most frequent other events
Showing 10 of 20
Most frequent other events
EventSLS-005Matching Placebo
FallInjury, poisoning and procedural complications32/1208/41
Muscular weaknessNervous system disorders22/1208/41
FatigueGeneral disorders19/1206/41
NeuromyopathyNervous system disorders18/1204/41
ConstipationGastrointestinal disorders15/1202/41
Urinary tract infectionInfections and infestations7/1205/41
DiarrhoeaGastrointestinal disorders13/1204/41
COVID-19Infections and infestations12/1203/41
DysarthriaNervous system disorders4/1204/41
Salivary hypersecretionGastrointestinal disorders4/1204/41

Baseline characteristics

Baseline Analysis Population includes only placebo participants from the Regimen E Efficacy Regimen Only (ERO) sample; shared placebo participants from other regimens are not included in the Baseline Analysis Population.

Age, Continuous
Age, Continuous(years)SLS-005Matching PlaceboTotal
Mean59.3 ± 10.7361.3 ± 10.1959.8 ± 10.60
Sex: Female, Male
Sex: Female, Male(Participants)SLS-005Matching PlaceboTotal
Female552479
Male651782
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SLS-005Matching PlaceboTotal
Hispanic or Latino213
Not Hispanic or Latino11540155
Unknown or Not Reported303
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SLS-005Matching PlaceboTotal
American Indian or Alaska Native000
Asian516
Native Hawaiian or Other Pacific Islander000
Black or African American213
White10939148
More than one race101
Unknown or Not Reported303
ALS Diagnosis from R El Escorial Criteria
ALS Diagnosis from R El Escorial Criteria(Participants)SLS-005Matching PlaceboTotal
Clinically Definite ALS441761
Clinically Possible ALS8311
Clinically Probable ALS401353
Clinically Probable ALS - Laboratory Supported28836
ALS Onset Location
ALS Onset Location(Participants)SLS-005Matching PlaceboTotal
Bulbar251136
Limb9327120
Multiple213
Respiratory022
Time Since Symptom Onset at Baseline
Time Since Symptom Onset at Baseline(Months)SLS-005Matching PlaceboTotal
Mean19.6 ± 8.6119.9 ± 8.2019.7 ± 8.48
Delay in ALS Symptom Onset and Diagnosis
Delay in ALS Symptom Onset and Diagnosis(Months)SLS-005Matching PlaceboTotal
Mean10.7 ± 6.8610.1 ± 4.8210.5 ± 6.39

10 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Healey Center for ALS at Mass General
    Boston, Massachusetts 02114, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Aug 2023, 18 months.

Results were first posted in Aug 2024, 1 year after primary completion.

Of 22 phase 2/3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 109. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2021
First posted
Nov 29, 2021
StartActual
Feb 21, 2022
Primary completionActual
Aug 25, 2023
CompletionActual
Aug 25, 2023
Results first posted
Aug 28, 2024
Last update
May 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05136885
Lead sponsor
Merit E. Cudkowicz, MD
Collaborators
Seelos Therapeutics, Inc.
Responsible party
Merit E. Cudkowicz, MD (Chief, Neurology Department, Massachusetts General Hospital) — Sponsor-investigator
First posted
Nov 29, 2021
Start date
Feb 21, 2022
Primary completion
Aug 25, 2023
Completion
Aug 25, 2023
Results posted
Aug 28, 2024
Last update
May 14, 2025

Study contacts

Merit Cudkowicz, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SLS-005

Start the discussion